BRUKER CORP
Bruker (NASDAQ:BRKR) reported Q2 2026 revenue of $838.5M, up 5.2% (organic growth 2.8%). Scientific Instruments bookings rose 10% organically with a book-to-bill above 1.0x. Non-GAAP EPS increased to $0.49; GAAP results included a non-cash goodwill impairment. Bruker kept 2026 non-GAAP EPS guidance at $2.10-$2.15 and updated revenue guidance to $3.54B-$3.57B for currency and tax effects.
US stock indices rose to record highs as investors weighed strong Q2 tech earnings expectations. Bloomberg Intelligence projects Q2 earnings up about 23% for S&P 500, with 86% of 322 reporters beating estimates. Markets priced a 59% chance of a 25 bp Fed hike and 85% for an ECB hike. SOX and AI chip stocks led; oil fell and energy stocks lagged.
The S&P 500 hit a new record high as Q2 earnings expectations rose. Bloomberg Intelligence projects Q2 earnings up about 23%, near Q1’s 30% surge. AI spending is expected to drive nearly 60% of S&P 500 EPS growth. So far, 86% of 322 companies beat estimates, per Bloomberg. Rate-hike odds are also discussed.
Over the past 7 days, alphai's AI scored 7 news stories mentioning BRKR (BRUKER CORP). Coverage has skewed bearish: 2 bullish, 1 neutral, and 4 bearish.
Recent BRKR coverage spans earnings, market movers and mergers & acquisitions.
In the last 30 days, BRKR insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($121K). The most active reporter was Munch Mark, EXEC VP&PRES BRUKER NANO INC., with 1 filing. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
Q2 results show improving order momentum in Scientific Instruments and margin expansion on an adjusted basis, while guidance is maintained with currency and tax updates.
BRKR’s revenue miss is a clear negative catalyst for the day.
Revenue miss is a negative catalyst for de-risking and potential multiple compression.
The guidance cut and revenue miss likely dominate the earnings beat, increasing near-term downside risk to estimates and sentiment.
The earnings mix is negative for revenue expectations despite a beat on non-GAAP EPS, likely keeping downside pressure on valuation until demand stabilizes.
alphai scores every news story that mentions BRKR with an AI model for sentiment and relevance, and aggregates insider trades from BRUKER CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
Bruker (NASDAQ:BRKR) reported Q2 2026 revenue of $838.5M, up 5.2% (organic growth 2.8%). Scientific Instruments bookings rose 10% organically with a book-to-bill above 1.0x. Non-GAAP EPS increased to $0.49; GAAP results included a non-cash goodwill impairment. Bruker kept 2026 non-GAAP EPS guidance at $2.10-$2.15 and updated revenue guidance to $3.54B-$3.57B for currency and tax effects.
6 min readUS stock indices rose to record highs as investors weighed strong Q2 tech earnings expectations. Bloomberg Intelligence projects Q2 earnings up about 23% for S&P 500, with 86% of 322 reporters beating estimates. Markets priced a 59% chance of a 25 bp Fed hike and 85% for an ECB hike. SOX and AI chip stocks led; oil fell and energy stocks lagged.
6 min readThe S&P 500 hit a new record high as Q2 earnings expectations rose. Bloomberg Intelligence projects Q2 earnings up about 23%, near Q1’s 30% surge. AI spending is expected to drive nearly 60% of S&P 500 EPS growth. So far, 86% of 322 companies beat estimates, per Bloomberg. Rate-hike odds are also discussed.
7 min readBruker (BRKR) shares fell 17.7% after the company reported Q2 results. Adjusted EPS of $0.49 beat estimates, but revenue was $838.5 million, below expectations. Bruker also cut full-year revenue guidance to a $3.56 billion midpoint, below analysts’ forecasts, driving the selloff despite the earnings beat.
3 min readBruker (NASDAQ:BRKR) reported Q2 CY2026 revenue of $838.5 million, up 5.2% year on year but below Wall Street estimates. Full-year revenue guidance of $3.56 billion (midpoint) was about 1% under consensus. Non-GAAP EPS was $0.49, above estimates, and the stock fell 11.9% to $56.63.
4 min readBRUKER CORP (BRKR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 brkr-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Bruker Reports Second Quarter 2026 Financial Results • Q2-26 Bruker Scientific Instruments (BSI) bookings up 10% organically year-over-year (yoy), with BSI book-to-bill >1.0x • Q2-26 revenue of $838.5 million, up +5.2% yoy; u
6 min readBruker (BRKR) will report Q2 earnings Tuesday before market open. The company previously beat revenue expectations with $823.4 million revenue, up 2.7% YoY, and beat EPS and organic revenue estimates. For Q2, analysts expect revenue growth of 7.2% YoY. The average analyst price target is $59.75 versus a $62.84 share price.
3 min readBruker Corp (Nasdaq: BRKR) said it acquired Noscendo GmbH’s DISQVER clinical metagenomics platform. DISQVER supports mNGS/WGS from cell-free human blood, screening for more than 11,000 microbes, with results in under 24 hours. DISQVER stays research-use-only while Bruker pursues diagnostic registration. Deal terms were not disclosed and it is not expected to be material to FY26.
4 min readThe article compares Q1 results across life-sciences tools stocks. West Pharmaceutical Services posted the biggest analyst estimate beat; its shares were up 18% to $323.85. Azenta reported $144.8M revenue (+1% YoY), missing expectations by 2.5%, and shares fell 5.8% to $23.19. Bruker revenue was $823.4M (+2.7%), beating by 3.4%, shares up 56% to $59.30. Illumina revenue was $1.09B (+4.8%), beating by 1.8%, shares up 29.1% to $163.68.
6 min readThe US Patent and Trademark Office's Patent Trial and Appeal Board has issued rulings in an inter partes review process involving Bruker and Seer. Both companies are claiming partial victories, indicating a mixed outcome in the patent dispute. The specific details of the patent claims and the board's decisions are not yet fully elaborated.
3 min read
